ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 143 filers reported holding ASCENDIS PHARMA A/S in Q1 2019. The put-call ratio across all filers is 0.49 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,041 | +4.9% | 481 | 0.0% | 0.01% | +20.0% |
| Q2 2023 | $42,929 | -16.8% | 481 | 0.0% | 0.01% | -28.6% |
| Q1 2023 | $51,573 | -12.2% | 481 | 0.0% | 0.01% | 0.0% |
| Q4 2022 | $58,745 | +19.9% | 481 | 0.0% | 0.01% | -12.5% |
| Q3 2022 | $49,000 | -12.5% | 481 | 0.0% | 0.01% | +14.3% |
| Q1 2022 | $56,000 | -13.8% | 481 | 0.0% | 0.01% | -12.5% |
| Q4 2021 | $65,000 | -15.6% | 481 | 0.0% | 0.01% | -11.1% |
| Q3 2021 | $77,000 | -38.9% | 481 | -49.9% | 0.01% | -47.1% |
| Q2 2021 | $126,000 | +1.6% | 961 | 0.0% | 0.02% | -22.7% |
| Q1 2021 | $124,000 | -12.7% | 961 | 0.0% | 0.02% | -37.1% |
| Q2 2020 | $142,000 | +31.5% | 961 | 0.0% | 0.04% | +16.7% |
| Q1 2020 | $108,000 | -1.8% | 961 | 0.0% | 0.03% | +3.4% |
| Q2 2019 | $110,000 | -2.7% | 961 | 0.0% | 0.03% | -6.5% |
| Q1 2019 | $113,000 | – | 961 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 10,719,555 | $1,003,779,130 | 19.76% |
| Q Global Advisors, LLC | 285,000 | $26,687 | 17.16% |
| Finepoint Capital LP | 163,772 | $15,335,610 | 7.64% |
| Avoro Capital Advisors LLC | 3,670,000 | $343,658,800 | 5.36% |
| Spyglass Capital Management LLC | 614,618 | $57,552,830 | 4.51% |
| Sofinnova Investments, Inc. | 754,032 | $70,607,556 | 4.45% |
| Saturn V Capital Management LP | 112,473 | $10,531,972 | 4.41% |
| DAFNA Capital Management LLC | 136,212 | $12,754,892 | 3.97% |
| ARS Investment Partners, LLC | 285,918 | $26,773,362 | 3.32% |
| Ghost Tree Capital, LLC | 85,000 | $7,959,400 | 2.62% |